Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals Plc ADR (NQ: CNTA )

4.320 +0.030 (+0.70%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,840
Open 4.390
Bid (Size) 4.000 (1)
Ask (Size) 4.610 (1)
Prev. Close 4.290
Today's Range 4.110 - 4.450
52wk Range 2.885 - 6.090
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
From Centessa Pharmaceuticals plc
Via GlobeNewswire

Performance

YTD
+38.02%
+38.02%
1 Month
-7.69%
-7.69%
3 Month
+22.73%
+22.73%
6 Month
+8.54%
+8.54%
1 Year
-4.00%
-4.00%

More News

Read More
Centessa Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
NASDAQ: CNTA Investor Alert: Deadline on November 28, 2022 in Lawsuit against Centessa Pharmaceuticals plc
Via SBWire
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
Via SBWire
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CENTESSA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
From Kahn Swick & Foti, LLC
Via Business Wire
CENTESSA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.